Evolva Holding Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time Being

Apr 01

Recent updates

Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time Being

Apr 01

Evolva Holding's (VTX:EVE) Shareholders Are Down 70% On Their Shares

Feb 13

We're Keeping An Eye On Evolva Holding's (VTX:EVE) Cash Burn Rate

Dec 21

CEO

Evolva Holding heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gerhard Lobmaier	Chief Operations Officer	3.3yrs	geen gegevens	geen gegevens
Thomas Schneckenburger	Head of Investor & Corporate Relations	no data	geen gegevens	geen gegevens
Philipp Frech	General Counsel & Secretary of the Board	2.3yrs	geen gegevens	geen gegevens
Anne De Vos	Head of Sales	no data	geen gegevens	geen gegevens
Astrid Schafer	Head of Innovation	6.3yrs	geen gegevens	geen gegevens
Luc Gruner	Executive Officer	6.8yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EVE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Beat In-Albon	Vice-Chairman of the Board	4yrs	CHF 160.00k	0.21% CHF 15.5k
Karl-Heinz Altmann	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jay Keasling	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Vincent Martin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jörg Bohlmann	Member of Scientific Advisory Board	8.7yrs	geen gegevens	geen gegevens
Birger Møller	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Karsten Kristiansen	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Stephan Schindler	Chairman of the Board	4yrs	CHF 95.00k	0.15% CHF 10.8k

4.0yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EVE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Evolva Holding Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Evolva Holding SA, Annual General Meeting, Apr 12, 2024

No independent directors

Evolva Holding SA Announces Management Appointments

No independent directors

Evolva Holding SA Announces Executive Changes

Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time Being

Recent updates

Evolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024

Evolva Holding SA, Annual General Meeting, Apr 12, 2024

Evolva Holding SA ADR - Sponsored to Be Deleted from OTC Equity

Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss Exchange

Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.

New major risk - Market cap size

We Think Evolva Holding (VTX:EVE) Has A Fair Chunk Of Debt

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Evolva Receives Approval for Veri-Te Resveratrol in Thailand

Evolva Receives FDA Approval for Veri-teTM Resveratrol in Taiwan

Would Evolva Holding (VTX:EVE) Be Better Off With Less Debt?

Evolva Holding SA (VTX:EVE) Screens Well But There Might Be A Catch

Full year 2022 earnings released: CHF0.04 loss per share (vs CHF0.047 loss in FY 2021)

No independent directors

First half 2022 earnings released: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021)

Evolva Holding SA Provides Revenue Guidance for the Full Year 2022 and 2025

Evolva Holding SA to Report Fiscal Year 2022 Results on Mar 09, 2023

Evolva Holding SA announced that it has received CHF 6.3226 million in funding

Evolva Holding SA Announces Management Appointments

Price target decreased to CHF0.21

No independent directors

Is Evolva Holding (VTX:EVE) Using Debt In A Risky Way?

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Price target decreased to CHF0.23

Full year 2021 earnings: EPS and revenues miss analyst expectations

Evolva Holding SA Announces Executive Changes

Forecast to breakeven in 2023

Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SA

Is Evolva Holding (VTX:EVE) Weighed On By Its Debt Load?

First half 2021 earnings released: CHF0.03 loss per share (vs CHF0.02 loss in 1H 2020)

Evolva Holding SA announced that it expects to receive CHF 20 million in funding from Nice & Green SA

Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time Being

Chief Financial Officer has left the company

Price target raised to CHF0.32

Earnings beat expectations, revenue disappoints

Evolva Announces Management Changes

Full year 2020 earnings released: CHF0.038 loss per share (vs CHF0.028 loss in FY 2019)

Evolva Holding's (VTX:EVE) Shareholders Are Down 70% On Their Shares

Evolva Launches L-Arabinose, a Natural Sugar Blocker and Reducing Sugar

New 90-day high: CHF0.24

We're Keeping An Eye On Evolva Holding's (VTX:EVE) Cash Burn Rate

Evolva Holding Sa Appoints Gerhard Lobmaier as Chief Operations Officer, Effective January 1, 2021

New 90-day low: CHF0.23

Processa Pharmaceuticals, Inc. Appoints Michael Floyd as Chief Operating Officer

Analysts update estimates

Evolva Holding SA to Report Fiscal Year 2020 Results on Feb 25, 2021

New 90-day high - CHF0.31

Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SA

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd